mRNA SARS-CoV-2 vaccine
ATC code: J07BX03 (COVID-19 vaccine)
Encodes full-length SARS-CoV-2 spike protein in lipid nanoparticles. After injection, maternal cells briefly synthesize spike, triggering IgG antibodies and T-cell response. mRNA degrades within days, does not integrate into DNA. 70-90% effectiveness against hospitalization in first 6 months, lower against infection.
First line
Prevention of severe COVID-19 in individuals ≥6 months. Per CDC ACIP 2024 and , an annual dose of the current composition is recommended for risk groups: age >65, immunocompromised, pregnant, healthcare workers. Dose 0.3 mL intramuscular.
First line
Active maternal immunization against COVID-19. CDC ACIP 2024 and SEGO 2023 recommend any trimester. No increased risk of miscarriage, preterm birth, or birth defects (Lancet 2022 meta-analysis, n>250,000).
First line
Comirnaty during breastfeeding. CDC ACIP 2024 and AEP CAV 2024 – fully compatible. mRNA and lipid nanoparticles do not transfer to milk in significant amounts. Spike antibodies pass into milk and provide passive infant protection.
Opens the checker prefilled with this drug. Pick the second one from your regimen.
Recommended in any trimester. Safe for mother and fetus per dozens of studies.
Fully compatible. mRNA does not transfer to milk significantly. Spike antibodies protect the infant. Hale L1.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
COVID-19 vaccine, mRNA (Pfizer-BioNTech) is evaluated for the following indications with varying evidence strength: COVID-19 prevention (evidence tier A), Vaccination during breastfeeding (evidence tier A), Maternal vaccination (evidence tier A). See the full indication matrix with dosing and citations above on this page.
Common side effects of COVID-19 vaccine, mRNA (Pfizer-BioNTech) (≥ 1 in 100): Injection-site pain (80%), Fatigue (60%), Headache (50%), Myalgia, Fever (10-20%), Axillary lymphadenopathy. See the Safety section for uncommon and serious reactions.
FDA category N. Recommended in any trimester. Safe for mother and fetus per dozens of studies.
Fully compatible. mRNA does not transfer to milk significantly. Spike antibodies protect the infant. Hale L1.
COVID-19 vaccine, mRNA (Pfizer-BioNTech) is contraindicated in: Anaphylaxis to previous dose or components (PEG, tromethamine); Myocarditis/pericarditis after previous dose (relative). Full list in the Safety section.